Transdel Pharmaceuticals Announces Positive Phase 3 Study Results For Lead Topical Pain Drug Ketotransdel(R)
Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, today announced positive top-line clinical results for its lead pain drug Ketotransdel®( )in a Phase 3 trial which evaluated the efficacy and safety of the drug in acute soft tissue injuries of the upper and lower extremities.
Related Posts
Tags: drug, ketotransdelr, lead, pain, pharmaceuticals, phase, positive, results, study, topical, transdel
This entry was posted on Sunday, October 11th, 2009 at 11:10 am and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
